Abstract: TH-PO0502
Psoriasis-Associated IgAN: Clinicopathological Findings from a Matched Case-Control Study and Preliminary Experience with IL-17 Inhibitor (IL-17i) plus Telitacicept Therapy
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Qi, Chenyang, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
- Pan, Xiaoxia, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
- Xie, Jingyuan, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
- Xu, Jing, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
Background
The distinct clinicopathological features of psoriasis-associated IgA nephropathy (IgAN-PSO) compared to primary IgAN (IgAN-PRI) remain insufficiently characterized. Optimal treatment strategies that address both the dermatological and renal components of IgAN-PSO have not been established.
Methods
We conducted a retrospective matched case-control study including 31 biopsy-confirmed IgAN-PSO patients and 62 matched primary IgAN controls (Figure1). Clinicopathological and immunological features were compared between 2 groups. For treatment analysis, five IgAN-PSO patients receiving combined IL-17i and telitacicept were each matched (Figure2).
Results
IgAN-PSO patients exhibited significantly higher segmental glomerulosclerosis proportion (0.24±0.18 vs. 0.14±0.13), more frequent interstitial plasma cell infiltration (87.1% vs. 66.1%,) and more severe renal tubular lesions compared to IgAN-PRI (P all <0.05) . Serum IgG, IgA and C4 were significantly elevated in IgAN-PSO (P all <0.05). Among the five IgAN-PSO patients treated with IL-17i and telitacicept (baseline CLIN-PATH 5-year ESRD risks: 17.57%, 14.11%, 0.49%, 0.77%, 2.18%), all achieved marked proteinuria reduction (3975→515 mg/24h over 20 months; 326.5→100 mg/24h over 3 months) with stable or improved eGFR, outperforming matched comparators on conventional therapy.
Conclusion
IgAN-PSO is pathologically distinct from primary IgAN, with greater glomerulosclerosis, plasma cell infiltration, tubular injury, and immunoglobulin dysregulation reflecting psoriasis-driven B-cell activation. Preliminary evidence supports combined IL-17 inhibitor and telitacicept therapy as a rational approach for IgAN-PSO. Prospective controlled trials are warranted.
Acknowledgment
We are grateful to Professor Anthony Chang from University of Chicago for his valuable insights and constructive suggestions that improved this work. We sincerely thank Dr. Pingyan Shen for her guidance and support, as well as her rich clinical expertise.
Funding
- Government Support – Non-U.S.